Ποια είναι η τιμή για Novo Nordisk A/S (NOVO-B)

Η τιμή για Novo Nordisk A/S (NOVO-B) είναι $47.55

Ποια είναι η κεφαλαιοποίηση αγοράς για Novo Nordisk A/S (NOVO-B)

Η κεφαλαιοποίηση αγοράς για Novo Nordisk A/S (NOVO-B) είναι $211.25B

Novo Nordisk A/S (NOVO-B) Δείκτης P/S

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Έτος	P/S Ratio	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

P/S Ratio

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	P/S Ratio	Διαφορά P/S Ratio	Χώρα
Eli Lilly and Company LLY.US	14.97	235.27%	US
Johnson & Johnson JNJ.US	6.31	41.28%	US
AbbVie Inc. ABBV.US	7.06	58.02%	US
Roche Holding AG RO.SW	4.66	4.33%	CH
Merck & Co., Inc. MRK.US	4.90	9.81%	US

Εταιρεία

P/S Ratio

Διαφορά P/S Ratio

Χώρα

Eli Lilly and Company

LLY.US

14.97

235.27%

Johnson & Johnson

JNJ.US

6.31

41.28%

AbbVie Inc.

ABBV.US

7.06

58.02%

Roche Holding AG

RO.SW

4.66

4.33%

Merck & Co., Inc.

MRK.US

4.90

9.81%

Novo Nordisk A/S

NOVO-B

Κατηγορία